Abstract：
ObjectiveThis study aimed to evaluate prevalence rates (PRs) of neurocognitive impairment and its potential moderators among patients with rheumatoid arthritis (RA). MethodA systematic review of the available literature and data extraction was undertaken on 6 August 2021, with the update by 14 September 2023, by two reviewers independently. Literature was screened for reported rates of prevalence of neurocognitive impairment in RA patients. The meta-analysis was performed using RStudio with the \"meta\" library. ResultsTwenty-two studies that fulfilled all selection criteria were carefully analyzed. The PR of neurocognitive impairment was 0.49 [0.38-0.61] across all studies included in the review; 0.75 [0.54-0.88] for the MoCA; 0.56 [0.40-0.72] for the MMSE; and 0.26 [0.16-0.38] for comprehensive batteries. The meta-regression results indicated that, depending on the measurement method, the percentage of subjects with positive rheumatoid factor, women ratio, mean age of participants, mean duration of RA, and percentage of domains that had to be impaired to diagnose neurocognitive impairment turned out to be statistically significant moderators. ConclusionsNeurocognitive impairment is a clinically relevant condition in many RA patients, and its prevalence is alarming high.
Rheumatoid arthritis (RA) is a chronic systemic disease that has a significant negative impact on functioning. Difficulties experienced by RA patients described in the literature may involve various organs and systems, including the central nervous system. The results obtained in the review indicate that cognitive impairment may affect, depending on the measurement method, up to approximately 75% of the patients. Due to potential limitations related to cognitive dysfunctions, such as reduced compliance or difficulties in everyday functioning, such a high prevalence of neurocognitive dysfunctions is an argument for screening RA patients and developing appropriate support methods.
Rheumatoid arthritis (RA) is a chronic systemic disease that has a significant negative impact on functioning. Difficulties experienced by RA patients described in the literature may involve various organs and systems, including the central nervous system. The results obtained in the review indicate that cognitive impairment may affect, depending on the measurement method, up to approximately 75% of the patients. Due to potential limitations related to cognitive dysfunctions, such as reduced compliance or difficulties in everyday functioning, such a high prevalence of neurocognitive dysfunctions is an argument for screening RA patients and developing appropriate support methods.
摘要：
目的本研究旨在评估类风湿关节炎（RA）患者神经认知障碍（PRs）的患病率及其潜在调节因素。方法2021年8月6日，由两名审稿人独立对现有文献和数据提取进行系统审查，并于2023年9月14日进行更新。对RA患者神经认知障碍患病率报告进行文献筛选。使用带有“meta”库的RStudio进行荟萃分析。结果对符合所有选择标准的22项研究进行了仔细分析。在该综述中包括的所有研究中，神经认知障碍的PR为0.49[0.38-0.61]；MoCA为0.75[0.54-0.88]；MMSE为0.56[0.40-0.72]；综合电池为0.26[0.16-0.38]。元回归结果表明，根据测量方法，类风湿因子阳性的受试者百分比，女性比例,参与者的平均年龄，RA的平均持续时间，和必须受损以诊断神经认知障碍的领域百分比被证明是统计学上显著的调节因素。结论神经认知障碍是许多RA患者的临床相关疾病，它的流行率令人震惊。
类风湿性关节炎(RA)是一种对功能具有显著负面影响的慢性系统性疾病。文献中描述的RA患者经历的困难可能涉及各种器官和系统，包括中枢神经系统.综述中获得的结果表明，认知障碍可能会影响，根据测量方法，约75%的患者。由于与认知功能障碍相关的潜在限制，如合规性降低或日常运作困难，如此高的神经认知功能障碍患病率是筛查RA患者和开发适当支持方法的依据.
类风湿性关节炎(RA)是一种对功能具有显著负面影响的慢性系统性疾病。文献中描述的RA患者经历的困难可能涉及各种器官和系统，包括中枢神经系统.综述中获得的结果表明，认知障碍可能会影响，根据测量方法，约75%的患者。由于与认知功能障碍相关的潜在限制，如合规性降低或日常运作困难，如此高的神经认知功能障碍患病率是筛查RA患者和开发适当支持方法的依据.
